QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 10 April 2017SV NewsSV Life Sciences Changes Name to SV Health Investors to Better Reflect the Firm's Longstanding Strategy and Focus
- 15 March 2017Portfolio NewsAutifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia
- 28 February 2017SV NewsDDF Acquires Small Molecule Library and Enters Strategic Partnership with Aptuit to Kickstart Dementia Drug Discovery Programmes
- 27 January 2017SV NewsKate Bingham receives BIA Lifetime Achievement Award at Annual Gala Dinner
- 21 October 2016Portfolio NewsLaunch of Dementia Discovery Fund New Fund Raises $100 Million to Deliver Novel Approaches to Treatment of Dementia
- 3 June 2016Portfolio NewsDDF invests in Gen2 Neuroscience Ltd
- 25 January 2016SV NewsSV appoints world-renowned Chief Scientific Officer to lead the new DDF investment team
- 7 January 2016Portfolio NewsDDF Makes First Investment In Alector LLC